After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration data and innovations related to its cell therapy treatment for male and female pattern hair...
www.accesswire.com
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
It is obvious that Shiseido breached the contract because they had to share the Phase 2 data with RepliCel But Shiseido didnt.
So Replicel will win the Court against Shiseido. After that it will be very interesting because then Shiseido has to share their data with Replicel. The other Option is that Shiseido will Buy the global rights of RCH-01.
Shiseido is doing a Phase 3 dose-finding trial. In the Phase II trial it was noticed that lower Cell concentrations of dermal sheath cup cells will lead to the best results.
Shiseido is now trialing with multiple injections and lower dosis. It could reach much better results.
If Shiseido is satisfied with the recently ongoing Phase 3 trial with lower doses and multiple injections then they wouldnt share the data with Replicel. They would buy the global rights of replicel.
So i just bought some RepliCel Shares at this Low price- Let’s See what will Happen
(0.3$ —> 20$ )